Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis

Clinical Infectious Diseases

Volumn 59, Issue 12, 2014, Pages 1696-1702

  Duarte, Rafael F ^a   Sánchez Ortega, Isabel ^a   Cuesta, Isabel ^b   Arnan, Montserrat ^a   Patiño, Beatriz ^a   Fernández De Sevilla, Alberto ^a   Gudiol, Carlota ^a   Ayats, Josefina ^c   Cuenca Estrella, Manuel ^b  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

antifungal prophylaxis; invasive aspergillosis; posaconazole; preemptive antifungal strategy; serum galactomannan assay

Indexed keywords

CORTICOSTEROID; GALACTOMANNAN; POSACONAZOLE; ANTIFUNGAL AGENT; FUNGUS ANTIGEN; MANNAN; TRIAZOLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ASSAY; CLINICAL TRIAL; CONSOLIDATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; FEMALE; HEMATOLOGY; HIGH RISK PATIENT; HUMAN; INCIDENCE; INDUCTION CHEMOTHERAPY; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALVAGE THERAPY; SERUM GALACTOMANNAN ASSAY; ASPERGILLOSIS; BLOOD;

ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; ASPERGILLOSIS; HUMANS; MANNANS; TRIAZOLES;

EID: 84924957050     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu673     Document Type: Article

References (39)

1. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32:358-66.
2. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
3. Gratwohl A, Brand R, Frassoni F, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005; 36:757-69.
4. Girmenia C, Raiola AM, Piciocchi A, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant 2014; 20:872-80.
5. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21.
6. Cuenca-Estrella M, Bassetti M, Lass-Flörl C, Rácil Z, Richardson M, Rogers TR. Detection and investigation of invasive mould disease. J Antimicrob Chemother 2011; 66(suppl 1):i15-24.
7. Marchetti O, Lamoth F, Mikulska M, et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 2012; 47:846-54.
8. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1417-27.
9. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev 2008; CD007394.
10. Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349:2366-7.
11. Mennink-Kersten MA, Klont RR, Warris A, Op den Camp HJ, Verweij PE. Bifidobacterium lipoteichoic acid and false ELISA reactivity in aspergillus antigen detection. Lancet 2004; 363:325-7.
12. Marr KA, Laverdiere M, Gugel A, LeisenringW. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40:1762-9.
13. Aubry A, Porcher R, Bottero J, et al. Occurrence and kinetics of falsepositive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol 2006; 44:389-94.
14. Racil Z, Kocmanova I, Lengerova M, Winterova J, Mayer J. Intravenous PLASMA-LYTE as a major cause of false-positive results of platelia Aspergillus test for galactomannan detection in serum. J Clin Microbiol 2007; 45:3141-2.
15. Surmont I, Stockman W. Gluconate-containing intravenous solutions: another cause of false-positive galactomannan assay reactivity. J Clin Microbiol 2007; 45:1373.
16. Asano-Mori Y, Kanda Y, Oshima K, et al. False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. J Antimicrob Chemother 2008; 61:411-6.
17. Cordonnier C, Botterel F, Ben Amor R, et al. Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin Microbiol Infect 2009; 15:81-6.
18. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41:1242-50.
19. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48:1042-51.
20. Girmenia C, Micozzi A, Gentile G, et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol 2010; 28:667-74.
21. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25:5471-89.
22. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-59.
23. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-47.
24. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-60.
25. Cornely OA, Bohme A, Buchheidt D, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009; 94:113-22.
26. Maertens J, Marchetti O, Herbrecht R, et al. Third European Conference on Infections in Leukemia Group. 2011. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011; 46:709-18.
27. Vehreschild JJ, Rüping MJ, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6-year experience of the Cologne AML cohort. J Antimicrob Chemother 2010; 65:1466-71.
28. Sánchez-Ortega I, Patiño B, Arnan M, et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant 2011; 46:733-9.
29. Ananda-Rajah MR, Grigg A, Downey MT, et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/ itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica 2012; 97:459-63.
30. Dellacasa CM, Busca A, Audisio E, et al. Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles. J Chemother 2014; 26: 315-20.
31. Pagano L, CairaM, Cuenca-Estrella M. The management of febrile neutropenia in the posaconazole era: a new challenge? Haematologica 2012; 97:963-5.
32. Fagan TJ. Nomogram for Bayes theorem. N Engl J Med 1975; 293:257.
33. Griner PF, Mayewski RJ, Mushlin AI, Greenland P. Selection and interpretation of diagnostic tests and procedures. Ann Intern Med 1981; 94:557-92.
34. Marr KA, Leisenring W. Design issues in studies evaluating diagnostic tests for aspergillosis. Clin Infec Dis 2005; 41(suppl 6):S381-6.
35. Donnelly JP, Leeflang MM. Galactomannan detection and diagnosis of invasive aspergillosis. Clin Infect Dis 2010; 50:1070-1.
36. Mausner JS, Kramer S, eds. Mausner & Bahn Epidemiology: an introductory text. Philadelphia: WB Saunders, 1985:221.
37. Borlenghi E, Cattaneo C, Capucci MA, et al. Usefulness of the MSG/ IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukemia developing pulmonary infiltrates. Ann Hematol 2007; 86:205-10.
38. Sánchez-Ortega I, Cuesta I, Patiño B, et al. Clinical efficacy and management of primary antifungal prophylaxis with posaconazole in high-risk haematology patients [abstract P950]. In: Program and abstracts of the 39th Annual Meeting of the European Group for Blood and Marrow Transplantation, London, UK, 2013.
39. García-Vidal C, Barba P, Arnan M, et al. Invasive aspergillosis complicating pandemic influenza A (H1N1) infection in severely immunocompromised patients. Clin Infect Dis 2011; 53:e16-19.